Expression of non-muscle myosin (NM) IIC in skeletal muscle cells. by Hiroki Hamaguchi (22783780)

ROCK inhibition decreases the motility of MHCC97H cells. by Ji-Gang Zhang (278184)

“…<p>(<b>A</b>) Y27632 inhibition delayed wound healing. …”

Decreased Incidence of Type 1 Diabetes in Young Finnish Children by Anna Parviainen (9343391)

“…In the middle age group, a significant decrease was observed only among females. …”

WT∶MU ratio is decreased in differentiated hOE-MSCs. by Nathalie Boone (234904)

Extent of demyelination is decreased following NgR knock down. by Fereshteh Pourabdolhossein (624998)

Mean (±95%CI) Rating of perceived exertion measured using a numeric scale (1–10) for the Nordic hamstring exercise, Sprint and control groups. by Nicholas J. Ripley (14709756)

Adoptive transfer of mature NK cells decreases the incidence of BA and improves survival, and the level of VP4 in cholangiocytes and the incidence of BA are decreased as the age of... by Yinrong Qiu (345978)

Biosynthetic flux decreases with biosynthetic ability and increases with nutrient flexibility. by Tugce Bilgin (154647)

PRV-induced infertility is caused by decreased P4 level. by Bing-Qian Su (8616981)

Inhibition of Rab5 Activity Decreases Fluid-Phase Uptake by Carsten Schnatwinkel (48)

Decreased HbNO production in HbE/ß-thal subjects. by Attaphon Chamchoi (5774669)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

PowerPoint Slides for: Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis by Bushinsky D.A. (3246690)

Resveratrol treatment decreases SIRT1 and SIRT2 levels. by Mehtap Kilic Eren (591048)

Fig 10 - by Torsten Schober (20485754)